Premium
Comparison of prophylactic use of intravenous immunoglobulin versus P entaglobin ® in pediatric patients after hematopoietic stem cell transplantation
Author(s) -
Azık Fatih,
Bayram Cengiz,
Erkoçoğlu Mustafa,
Tezer Hasan,
Yazal Erdem Arzu,
Işık Pamir,
Avcı Zekai,
Özbek Namık,
Tavil Betül,
Tunc Bahattin
Publication year - 2016
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12636
Subject(s) - medicine , hematopoietic stem cell transplantation , adverse effect , bacteremia , placebo , neutropenia , transplantation , randomized controlled trial , antibody , surgery , antibiotics , immunology , chemotherapy , alternative medicine , pathology , microbiology and biotechnology , biology
There are few studies evaluating the use of I g M ‐enriched IVIG ( P entaglobin ® ) in HSCT recipients. This study aimed to compare the efficacy of prophylactic use of IVIG versus prophylactic use of P entaglobin ® within the first 100 days after allogeneic HSCT . We performed a prospective, randomized study of the use of prophylactic IVIG versus prophylactic use of P entaglobin ® in patients after allogeneic HSCT . The first dose of IVIG or P entaglobin ® was given before conditioning regimen and after transplant was given on day +1, +8, +15, and +22. And then, it was given if I g G level was below 400 mg/dL. Twenty‐seven patients in IVIG group and 32 patients in P entaglobin ® group were included in the study. There were no significant differences in the duration of neutropenia, hospitalization, fever, and in the number of pyrexial episode, septicemia, bacteremia, local infection, CMV infection, acute GVHD , VOD , and adverse events between the IVIG group and P entaglobin ® group. Randomized placebo‐controlled trials are needed to conclude that utilization of IVIG or P entaglobin ® has no beneficial effect in HSCT .